Hematology-Oncology
Latest news
316 articles · 20 / page
Large-Cell Transformation of Mycosis Fungoides: Clinical Patterns, Prognostic Insights, and Implications for Staging
Large-cell transformation in mycosis fungoides marks an aggressive disease subset with distinct prognostic groups and poor survival, highlighting the need for tailored treatment and integration into staging systems.
CLIPI: A New Prognostic Index Transforming Risk Stratification in Advanced Cutaneous Lymphomas
The CLIPI prognostic index refines risk stratification in advanced mycosis fungoides and Sézary syndrome, identifying distinct survival groups to guide personalized treatment decisions and improve outcomes.
Genomic Insights into Pirtobrutinib Efficacy and Resistance Mechanisms in Relapsed/Refractory Chronic Lymphocytic Leukemia
This article explores genomic factors influencing response and resistance to pirtobrutinib, a reversible BTK inhibitor, in relapsed/refractory CLL patients previously treated with covalent BTK inhibitors, highlighting clonal mutation dynami
Efficacy of Rituximab Combined with Pentostatin or Bendamustine in Multiply Relapsed Hairy Cell Leukemia: Insights from a Phase 2 Trial
This phase 2 trial reveals that both pentostatin-rituximab and bendamustine-rituximab combinations achieve high response rates exceeding rituximab alone in multiply relapsed or refractory hairy cell leukemia, with potential superiority tren
Unveiling Distinct Biological Subtypes of Chronic GVHD in Pediatric Hematopoietic Cell Transplantation: Toward Personalized Management
Recent research identifies three unique biological subtypes of chronic graft-versus-host disease (cGvHD) in children post-hematopoietic cell transplantation, offering potential pathways for tailored treatments and improved outcomes.
Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy
Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal
Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial
The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in adva
Preclinical Progress of Glofitamab Combinations: Pioneering Therapeutics in Non-Hodgkin Lymphoma Management
Glofitamab, a CD20×CD3 T-cell engager, demonstrates promising synergistic effects in combination with chemotherapy and novel immunotherapies, addressing resistance mechanisms in non-Hodgkin lymphoma preclinical models and supporting future
Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact
MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.
Personalized Prediction of Platelet Transfusion Outcomes in Preterm Infants with Severe Thrombocytopenia
A dynamic model predicts individualized risk of major bleeding or death with or without prophylactic platelet transfusion in preterm infants, allowing tailored clinical decisions based on evolving patient status.
Ibrutinib-Rituximab versus Immunochemotherapy: A Paradigm Shift in First-Line Treatment for Older Mantle Cell Lymphoma Patients
The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherap
Evaluating Anemia-Related YouTube Videos: Reliable Education or Misinformation Risk?
A recent study assessed the quality, reliability, and popularity of anemia-related videos on YouTube, revealing moderate variability and highlighting the importance of health professionals’ involvement to ensure accurate online content.
Evaluating Radiation Risks from Medical Imaging in Pediatrics: Implications for Hematologic Cancer
A large cohort study links radiation exposure from pediatric medical imaging to a modest but significant increase in hematologic cancer risk, underlining the need for judicious imaging use in children and adolescents.
Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy
Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocy
Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS
A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leu
Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial
A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.
Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis
A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and comb
Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety
Nanobody-based dual-targeting BCMA CAR T-cell therapy demonstrates high response rates and manageable safety in relapsed/refractory plasma cell myeloma, including high-risk subgroups.
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the
PET-Guided BrECADD Therapy: A Breakthrough for Older Patients with Advanced-Stage Classic Hodgkin Lymphoma
This phase II HD21 trial cohort demonstrates that PET-guided BrECADD chemotherapy is feasible, effective, and well-tolerated in older patients with advanced-stage classic Hodgkin lymphoma, achieving high complete remission and survival rate
Browse by specialty
Open language-specific specialty feeds and department pages.